KRAScendo 1: divarasib met its primary PFS endpoint and improved OS vs a sotorasib-dominant control.
OS: 17.7 vs 12.0 mo; HR 0.56.

Is OS now the benchmark for next-generation KRAS G12C inhibitors?

https://www.nejm.org/doi/10.1056/NEJMoa2605703

@FSkoulidis @myESMO @OncoAlert @OncoDaily #ESMO26